If you have been reading about LC-MS/MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-28. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Bernard Weinstein Christopher Payne (1990), photographer Peter Mendelsund (1991), creative director of The Atlantic, graphic designer Rachel Feinstein (1993), sculptor Alison Castle (1995), photographer and book editor, daughter of artist Wendell Castle Ricardo Cortés (1995), illustrator, It's Just a Plant Damon Winter (1997), Pulitzer Prize-winning photographer for The New York Times Damon Rich (1997), urban designer, 2017 MacArthur Fellow Nicola López (1998), artist, professor at the Columbia University School of the Arts Emily Abruzzo (2000), co-founder of Abruzzo Bodziak Architects Steffani Jemison (2003), artist Ariel Schrag (2003), cartoonist Amanda Phingbodhipakkiya (2010), Thai-American artist known for the project Beyond Curie
== Further reading == Chesnut, D. B.; Savin, A. (1999). "The Electron Localization Function (ELF) Description of the PO Bond in Phosphine Oxide". Journal of the American Chemical Society. 121 (10): 2335–2336. Bibcode:1999JAChS.121.2335C. doi:10.1021/ja984314m. Alkorta, Ibon; Sánchez-Sanz, Goar; Elguero, José; Del Bene, Janet E. (2014). "Pnicogen Bonds between X═PH3 (X = O, S, NH, CH2) and Phosphorus and Nitrogen Bases". The Journal of Physical Chemistry A. 118 (8): 1527–1537. Bibcode:2014JPCA..118.1527A. doi:10.1021/jp411623h. PMID 24547683.
== Funding == Gavi runs in five-year funding cycles which enables it to negotiate long-term deals with vaccine manufacturers. Industrialised countries are Gavi's principal donors, providing approximately three-quarters of the total funding. All donor governments are represented on the Gavi Board through a constituency system (i.e. one donor country will represent several donors in their constituency). In the period of 2016–2020, Gavi received US$9.3 billion, with over half of the total funding provided by the three largest donors: the UK, the Bill & Melinda Gates Foundation (BMGF), and the USA (see table). Following the Global Vaccine Summit in June 2020 hosted in the UK, US$8.8 billion was raised for the funding cycle 2021 to 2025; exceeding the target of US$7.4 billion. This included US$2 billion from the UK, US$1.6 billion from the Gates Foundation and US$1 billion from Norway. For the 2026-2030 funding cycle, the UK announced it was committing to donate £1.25 billion (roughly US$1.7 billion), The Gates Foundation announced a US$1.6 billion contribution, and the US announced it was donating US$0. As a result, Gavi announced it would fall almost US$3 billion short of its budget aim of US$11.9 billion with a total budget of US$9 billion.
=== India === The Indian Armed Forces issues a host of rations including the One Man Combo Pack Ration, Mini Combo Pack, Survival Ration, and Main Battle Tank Rations. The shelf-life of the ration is 12 months. India has adopted retort processing technology for combat rations. The rations use pre-cooked thermostabilized entrees in a plastic-foil laminate retort pouch. The ration does not require cooking and the contents may be eaten cold, though warming is preferred. An entire day's worth of food, plus accessory items, is packed inside a heavy-duty olive green plastic bag with pasted on label. The menu consists of several different Vegetarian and Non-Vegetarian products that cater to Indian tastes, such as sooji halwa, chapatis, tea mix, chicken biryani, chicken curry, Kebab, Tandoori, Panneer, Organic Egg, Butter naan, mutton biryani, Mutton curry, Vegetable biryani, rajma curry, dal fry, jeera rice, Dal makhani, vegetable pulav and mixed vegetable curry, alongside pickled hot seasoning, in small plastic pouches. The One Man Combo Pack consists of early morning tea, breakfast, mid morning tea, lunch, evening tea, and dinner. The menus feature both dehydrated and ready-to-eat products, and include a folding stove and hexamine fuel tablets. The ration weighs 880 grams and provides 4,100 kcal (17,000 kJ). The Mini Combo Pack is a simplified version of the One Man Combo Pack, weighing 400 g and providing 1,520 kcal (6,400 kJ). The Survival Ration consists of a soft bar and chikki.
== Internal angle bisectors and incenter == The internal angle bisectors are segments in the interior of the triangle reaching from one vertex to the opposite side and bisecting the vertex angle into two equal angles. The angle bisectors ta etc. satisfy
Sources: en.wikipedia.org
replication rate The speed at which deoxyribonucleotides are incorporated into an elongating chain by DNA polymerases during DNA replication; or more generally the speed at which any chromosome, genome, cell, or organism makes a complete, independently functional copy of itself.
Azvudine is an antiviral drug which acts as a reverse transcriptase inhibitor. It was discovered for the treatment of hepatitis C and has since been investigated for use against other viral diseases such as AIDS and COVID-19, for which it was granted conditional approval in China. Azvudine was first discovered in 2007. It costs 350 Chinese yuan per 7 days for COVID, as of November 2022.
=== 5 July === One person was killed in a Russian airstrike in Donetsk Oblast. In Russia, the governor of Rostov Oblast claimed that ten drones were shot down, causing a fire in Rostov-on-Don. The governor of Krasnodar Krai claimed that a child was killed in a drone attack in Primorsko-Akhtarsk.
=== Development of Therapeutic and Diagnostic Procedures === This program studies molecular mechanisms of diseases including reproductive disorders, diabetes, and autoimmune conditions. It uses molecular biology and animal models to develop diagnostic kits and therapeutic strategies.
==== Announcement ==== In mid-March 1989, both research teams were ready to publish their findings, and Fleischmann and Jones had agreed to meet at an airport on 24 March to send their papers to Nature via FedEx. Fleischmann and Pons, however, pressured by the University of Utah, which wanted to establish priority on the discovery, broke their apparent agreement, disclosing their work at a press conference on 23 March (they claimed in the press release that it would be published in Nature but instead submitted their paper to the Journal of Electroanalytical Chemistry). Jones, upset, faxed in his paper to Nature after the press conference. Fleischmann and Pons' announcement drew wide media attention, as well as attention from the scientific community. The 1986 discovery of high-temperature superconductivity had made scientists more open to revelations of unexpected but potentially momentous scientific results that could be replicated reliably even if they could not be explained by established theories. Many scientists were also reminded of the Mössbauer effect, a process involving nuclear transitions in a solid. Its discovery 30 years earlier had also been unexpected, though it was quickly replicated and explained within the existing physics framework.
Sources: en.wikipedia.org
=== Patenting === In the U.S., efforts into creating a chimeric entity appeared to be legal when the topic first came up. Developmental biologist Stuart Newman, a professor at New York Medical College in Valhalla, N.Y., applied for a patent on a human-animal chimera in 1997 as a challenge to the U.S. Patent and Trademark Office and the U.S. Congress, motivated by his moral and scientific opposition to the notion that living things can be patented at all. Prior legal precedent had established that genetically engineered entities, in general, could be patented, even if they were based on beings occurring in nature. After a seven-year process, Newman's patent finally received a flat rejection. The legal process had created a paper trail of arguments, giving Newman what he claimed was a victory. The Washington Post ran an article on the controversy that stated that it had raised "profound questions about the differences—and similarities—between humans and other animals, and the limits of treating animals as property."
Cross-matching or crossmatching is a test performed before a blood transfusion as part of blood compatibility testing. Normally, this involves adding the recipient's blood plasma to a sample of the donor's red blood cells. If the blood is incompatible, the antibodies in the recipient's plasma will bind to antigens on the donor red blood cells. This antibody-antigen reaction can be detected through visible clumping or destruction of the red blood cells, or by reaction with anti-human globulin. Along with blood typing of the donor and recipient and screening for unexpected blood group antibodies, cross-matching is one of a series of steps in pre-transfusion testing. In some circumstances, an electronic cross-match can be performed by comparing records of the recipient's ABO and Rh blood type against that of the donor sample. In emergencies, blood may be issued before cross-matching is complete. Cross-matching is also used to determine compatibility between a donor and recipient in solid organ transplantation including heart/lung transplation.
Oxygen primary ions are often used to investigate electropositive elements due to an increase of the generation probability of positive secondary ions, while caesium primary ions often are used when electronegative elements are being investigated. For short pulsed ion beams in static SIMS, LMIGs are most often deployed for analysis; they can be combined with either an oxygen gun or a caesium gun during elemental depth profiling, or with a C60+ or gas-cluster ion source during molecular depth profiling.
=== Patents === U.S. Patent No. 8871759 was published in 2014 for the specified compounds useful for hepatitis C virus NS5A inhibitors. The patent protects Merck's formulation for the drug and its other associated salt forms, hydrates, solvates, prodrugs and isomers. U.S. Patent No. 7973040 was published in 2011. The patent protects the invention by Merck of the macrocyclic compound within the formula as an inhibitor for NS3 protease. The patent describes the formulation of the compound and its salts, along with its uses and potential implications as an HCV antiviral treatment.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.